Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. / Kjaer, Andreas; Kristoffersen, Ulrik Sloth; Tarnow, Lise; Parving, Hans-Henrik; Hesse, Birger.
In: Diabetes Research and Clinical Practice, Vol. 84, No. 1, 2009, p. 34-8.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients
AU - Kjaer, Andreas
AU - Kristoffersen, Ulrik Sloth
AU - Tarnow, Lise
AU - Parving, Hans-Henrik
AU - Hesse, Birger
N1 - Export Date: 4 November 2009Source: Scopus
PY - 2009
Y1 - 2009
N2 - BACKGROUND: We have previously found that acute intravenous infusion of an ACE inhibitor normalized the reduced coronary vasomotor function in type 2 diabetes. The aim of the present study was to extend this investigation to an angiotensin II receptor blocker (ARB) administered orally in normotensive, asymptomatic type 2 diabetes patients without albuminuria. RESULTS: Fourteen type 2 diabetes patients were included. Each patient had myocardial perfusion measured by PET at three occasions: at baseline, following 3 weeks of treatment with 50mg/d and following another 3 weeks of treatment with 100mg/d of losartan. Baseline myocardial perfusion was similar at all three sessions (0.89+/-0.05, 0.90+/-0.08 and 0.84+/-0.05mL/(ming) tissue, respectively). Likewise, maximal hyperaemic perfusion after i.v. dipyridamole (0.56mg/kg bwt) was low but similar at the three sessions (2.01+/-0.14, 2.05+/-0.17 and 1.90+/-0.20mL/(ming) tissue, respectively). Myocardial perfusion reserve, i.e. maximal hyperaemic flow relative to baseline flow, was also low, but similar before and after treatment with losartan (2.36+/-0.24, 2.44+/-0.24 and 2.62+/-0.42mL/(ming) tissue, respectively). CONCLUSIONS: Oral treatment with an ARB did not normalize coronary vasomotor function in type 2 diabetes patients without cardiovascular disease.
AB - BACKGROUND: We have previously found that acute intravenous infusion of an ACE inhibitor normalized the reduced coronary vasomotor function in type 2 diabetes. The aim of the present study was to extend this investigation to an angiotensin II receptor blocker (ARB) administered orally in normotensive, asymptomatic type 2 diabetes patients without albuminuria. RESULTS: Fourteen type 2 diabetes patients were included. Each patient had myocardial perfusion measured by PET at three occasions: at baseline, following 3 weeks of treatment with 50mg/d and following another 3 weeks of treatment with 100mg/d of losartan. Baseline myocardial perfusion was similar at all three sessions (0.89+/-0.05, 0.90+/-0.08 and 0.84+/-0.05mL/(ming) tissue, respectively). Likewise, maximal hyperaemic perfusion after i.v. dipyridamole (0.56mg/kg bwt) was low but similar at the three sessions (2.01+/-0.14, 2.05+/-0.17 and 1.90+/-0.20mL/(ming) tissue, respectively). Myocardial perfusion reserve, i.e. maximal hyperaemic flow relative to baseline flow, was also low, but similar before and after treatment with losartan (2.36+/-0.24, 2.44+/-0.24 and 2.62+/-0.42mL/(ming) tissue, respectively). CONCLUSIONS: Oral treatment with an ARB did not normalize coronary vasomotor function in type 2 diabetes patients without cardiovascular disease.
U2 - 10.1016/j.diabres.2009.01.010
DO - 10.1016/j.diabres.2009.01.010
M3 - Journal article
C2 - 19233497
VL - 84
SP - 34
EP - 38
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
IS - 1
ER -
ID: 12796688